Cadrenal Therapeutics, Common Stock Probability of Future Stock Price Finishing Over 16.74
| CVKD Stock | 16.17 1.68 11.59% |
Cadrenal |
Cadrenal Therapeutics, Target Price Odds to finish over 16.74
The tendency of Cadrenal Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over 16.74 or more in 90 days |
| 16.17 | 90 days | 16.74 | about 9.69 |
Based on a normal probability distribution, the odds of Cadrenal Therapeutics, to move over 16.74 or more in 90 days from now is about 9.69 (This Cadrenal Therapeutics, Common probability density function shows the probability of Cadrenal Stock to fall within a particular range of prices over 90 days) . Probability of Cadrenal Therapeutics, price to stay between its current price of 16.17 and 16.74 at the end of the 90-day period is about 5.93 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.47 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cadrenal Therapeutics, will likely underperform. Additionally Cadrenal Therapeutics, Common has an alpha of 0.7931, implying that it can generate a 0.79 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cadrenal Therapeutics, Price Density |
| Price |
Predictive Modules for Cadrenal Therapeutics,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cadrenal Therapeutics,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cadrenal Therapeutics, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cadrenal Therapeutics, is not an exception. The market had few large corrections towards the Cadrenal Therapeutics,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cadrenal Therapeutics, Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cadrenal Therapeutics, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.79 | |
β | Beta against Dow Jones | 1.47 | |
σ | Overall volatility | 1.97 | |
Ir | Information ratio | 0.11 |
Cadrenal Therapeutics, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cadrenal Therapeutics, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cadrenal Therapeutics, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cadrenal Therapeutics, is way too risky over 90 days horizon | |
| Cadrenal Therapeutics, appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (8.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cadrenal Therapeutics, generates negative cash flow from operations | |
| Cadrenal Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| About 34.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 150000 shares by Jeff Cole of Cadrenal Therapeutics, at 0.94 subject to Rule 16b-3 |
Cadrenal Therapeutics, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cadrenal Stock often depends not only on the future outlook of the current and potential Cadrenal Therapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cadrenal Therapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 868.2 K | |
| Cash And Short Term Investments | 8.4 M |
Cadrenal Therapeutics, Technical Analysis
Cadrenal Therapeutics,'s future price can be derived by breaking down and analyzing its technical indicators over time. Cadrenal Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cadrenal Therapeutics, Common. In general, you should focus on analyzing Cadrenal Stock price patterns and their correlations with different microeconomic environments and drivers.
Cadrenal Therapeutics, Predictive Forecast Models
Cadrenal Therapeutics,'s time-series forecasting models is one of many Cadrenal Therapeutics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cadrenal Therapeutics,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cadrenal Therapeutics,
Checking the ongoing alerts about Cadrenal Therapeutics, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cadrenal Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cadrenal Therapeutics, is way too risky over 90 days horizon | |
| Cadrenal Therapeutics, appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (8.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cadrenal Therapeutics, generates negative cash flow from operations | |
| Cadrenal Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| About 34.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 150000 shares by Jeff Cole of Cadrenal Therapeutics, at 0.94 subject to Rule 16b-3 |
Check out Cadrenal Therapeutics, Backtesting, Cadrenal Therapeutics, Valuation, Cadrenal Therapeutics, Correlation, Cadrenal Therapeutics, Hype Analysis, Cadrenal Therapeutics, Volatility, Cadrenal Therapeutics, History as well as Cadrenal Therapeutics, Performance. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.